Skip to main content

Table 3 Relationship of four classes based on PD-L1 expression and CD8+ TILs

From: Classification of gallbladder cancer by assessment of CD8+ TIL and PD-L1 expression

  Subgroup I Subgroup II Subgroup III Subgroup IV
  CD8high
PD-L1
CD8high
PD-L1+
CD8low
PD-L1
CD8low
PD-L1+
Clinical parameters
n (%)
(n = 12) (n = 21) (n = 18) (n = 15)
Age median (range) 65 (50–79) 64 (29–75) 66 (48–79) 70 (45–81)
Sex (Female) 7 (58%) 12 (57%) 10 (56%) 9 (60%)
TNM stage (III + IV) 7 (58%) 11 (52%) 14 (78%) 11 (73%)
Risk factors
 Gallstone 3 (25%) 13 (62%) 11 (61%) 9 (60%)
 Diabetes 4 (33%) 6 (29%) 7 (39%) 3 (20%)
 Hypertension 4 (33%) 8 (38%) 8 (44%) 5 (33%)
 Cholecystitis 7 (58%) 12 (57%) 14 (78%) 10 (67%)
Jaundice 0 (0%) 6 (29%) 4 (22%) 4 (27%)
Completed resection 8 (67%) 16 (76%) 11 (61%) 11 (73%)
CEA (>  5 μg/L) 2 (17%) 5 (24%) 4 (22%) 9 (60%)
CA19–9 (>  34 U/mL) 4 (33%) 13 (62%) 11 (61%) 7 (58%)
Liver dysfunction
 ALT (>  40 U/L)     
 AST (>  35 U/L) 1 (8%) 5 (24%) 5 (28%) 4 (27%)
 TBil (>  22.2 μmol/L) 3 (25%) 5 (24%) 6 (33%) 5 (33%)
 DBil (>  6.8 μmol/L) 3 (25%) 7 (33%) 5 (28%) 5 (33%)
 GGT (>  45 U/L) 1 (8%) 7 (33%) 5 (28%) 5 (33%)
 ALP (>  135 U/L) 3 (25%) 7 (33%) 5 (28%) 5 (33%)
  2 (17%) 9 (43%) 5 (28%) 4 (27%)
Pathological features
Differentiation (Poor) 5 (42%) 12 (57%) 9 (50%) 12 (80%)
Tumor size, cm (median, range) 2.4 (0.6–7.5) 3.5 (0.5–7.0) 3.0 (0.6–6.0) 2.0 (0.8–7.0)
Immunohistochemistry
 CD133+ in TCs, n (%) 5 (42%) 9 (43%) 6 (33%) 7 (58%)
 PD-1+ in TILs, n (%) 7 (58%) 9 (43%) 6 (33%) 11 (73%)
 PD-L2+ in TCs, n (%) 5 (42%) 17 (81%) 9 (50%) 13 (87%)
 CD8+ TILs density 60.5 79 28 27
 (median, range) (47–167) (49–275) (4–42) (8–46)
Adjuvant treatment
 Chemotherapy, n (%) 7 (58%) 12 (57%) 13 (72%) 8 (53%)
 Radiotherapy, n (%) 2 (17%) 5 (24%) 4 (22%) 4 (27%)
 Others, n (%) 3 (25%) 8 (33%) 6 (33%) 4 (27%)
 No, n (%) 2 (17%) 4 (19%) 2 (11%) 2 (13%)
Palliative treatment at stage IV
 With therapy, n (%) 8 (67%) 16 (76%) 15 (83%) 12 (80%)
 Without therapy, n (%) 4 (33%) 5 (24%) 3 (17%) 3 (20%)